Why Is Precigen (PGEN) Stock Up +30% Today?
Key Takeaways
- PGEN shares are surging approximately +30% in Thursday's trading session, from a prior close of $3.10 to approximately $4.03, as of mid-session on March 26, 2026.
- The primary catalyst is Precigen's blockbuster Q1 2026 revenue guidance — the company expects Q1 revenue to exceed $18 million, a staggering 429% sequential increase from Q4 2025's $3.4 million.
- The guidance is powered by rapidly accelerating commercial uptake of Papzimeos, the company's FDA-approved therapy for recurrent respiratory papillomatosis (RRP), which only launched in November 2025.
- Full-year 2025 revenue came in at $9.7 million — beating analyst estimates — and rose 149% year-over-year, marking Precigen's transformation into a commercial-stage biotech.
- Payer coverage for Papzimeos expanded from roughly 170 million to 215 million lives, including major commercial, Medicare, and Medicaid plans.
- Traders and analysts are watching Papzimeos' Q1 execution closely, with Wall Street price targets ranging from $8 to $9 per share — implying significant additional upside if commercial momentum holds.
Opening Summary
Precigen, Inc. (PGEN) is a Maryland-based clinical and commercial-stage biopharmaceutical company specializing in gene and cell therapy platforms, most notably the AdenoVerse and UltraCAR-T technologies, targeting cancers and rare diseases. On Thursday, March 26, 2026, shares surged approximately +30%, moving from a prior session close of approximately $3.10 to an intraday price near $4.03, with the market still open as of this writing. The move was triggered by the company's Q4 and full-year 2025 earnings report — released after market close on Wednesday, March 25 — in which management delivered a forward-looking Q1 2026 revenue forecast that sent analysts scrambling to revise their models upward.
Earnings Results: Revenue Beat and a Pivotal Year
Precigen's full-year 2025 revenue reached $9.7 million, a 149% increase compared to 2024, and ahead of analyst consensus estimates of approximately $8.3 million. Net product revenue for Q4 2025 alone came in at $3.4 million, a figure that represents the first commercial quarter of Papzimeos sales since the product's launch in November 2025. While the company reported a net GAAP loss of $429.6 million for the full year — driven predominantly by significant non-cash accounting items — the adjusted net loss was considerably narrower, at $0.35 per share. Management expressed confidence that the company is on track to reach cash flow breakeven by the end of 2026.
Q1 2026 Guidance: The Real Market Catalyst
The standout moment from the earnings call was management's Q1 2026 revenue guidance: the company expects revenue to exceed $18 million for the quarter — a 429% sequential jump from Q4 2025's $3.4 million. This figure dramatically outpaced analyst expectations, which had been anchored to modest launch-phase ramp assumptions. Management noted that prescriber momentum at major medical centers and community practices has been accelerating materially, with Papzimeos gaining traction across all key specialty channels. The guidance also signals that Precigen's pivot from a research-stage entity to a revenue-generating commercial biotech is progressing ahead of schedule — a narrative shift that the market responded to emphatically.
Papzimeos: A Rare Disease Franchise Gaining Commercial Footing
Papzimeos — approved by the FDA in August 2025 for the treatment of adult recurrent respiratory papillomatosis (RRP) caused by human papillomavirus (HPV) — is now the clear commercial engine powering PGEN's growth story. RRP is a rare but serious condition characterized by recurrent benign tumors of the upper respiratory tract requiring frequent surgical removal. Clinical trial data showed a 51% complete response rate, and the drug's clinical profile has enabled rapid payer adoption. As of early January 2026, payer coverage expanded to 215 million covered lives, up from approximately 170 million, encompassing nearly all major commercial, Medicare, and Medicaid payers — a significant commercial milestone that removes a key barrier to prescribing.
Market Context and Trading Activity
Volume in PGEN on Thursday is running sharply elevated relative to the stock's average daily trading volume of roughly 4 million shares, consistent with a major catalyst-driven move. The stock's 52-week range spans from $1.11 to $5.47, and today's rally brings PGEN back toward the upper half of that range. The broader biotech sector and small-cap indices are not exhibiting comparable gains, suggesting this is a company-specific, earnings-driven move rather than a sympathy play or sector-wide rotation. The stock had pulled back roughly 8-9% over the prior month before today's surge, meaning buyers who added on weakness ahead of earnings are seeing outsized returns. On a technical basis, PGEN is now trading well above its 50-day moving average, a level that had previously acted as resistance.
Trending AI Robots
For traders looking to systematically capitalize on momentum moves like today's action in PGEN, Tickeron's Trending AI Robots page offers a curated selection of the platform's best-performing automated trading bots under current market conditions. Tickeron operates hundreds of AI-powered bots spanning thousands of tickers across equities, ETFs, and other asset classes — but only the strongest performers, filtered by recent results, are featured in the Trending AI Robots section. Each bot varies by trading strategy, holding timeframe, risk profile, and the symbols it targets, giving traders the flexibility to find an approach that aligns with their goals. Whether you're focused on biotech volatility, momentum breakouts, or diversified swing trading, exploring the Trending AI Robots section is a practical starting point for integrating systematic AI-driven strategies into your portfolio.
What Comes Next for PGEN
The single most important near-term data point for PGEN shareholders will be the Q1 2026 actual revenue report, expected in May 2026, which will confirm whether the company achieves or surpasses its own >$18 million guidance. Any deviation — positive or negative — from that figure will likely produce a significant market reaction given how much today's rally prices in execution success. Analysts will also be watching the trajectory of new prescriber additions, payer reimbursement approvals in remaining segments, and patient persistence data for Papzimeos. On the pipeline side, Precigen continues to advance its UltraCAR-T programs (PRGN-3005 and PRGN-3006) in Phase 1b trials for ovarian cancer and acute myeloid leukemia — milestones that could provide additional upside catalysts later in 2026. Key risks include commercial execution shortfalls, competitive entrants into the RRP therapeutic space, and the company's ongoing cash consumption as it scales its commercial infrastructure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PGEN's RSI Oscillator ascends from oversold territory
The RSI Indicator for PGEN moved out of oversold territory on March 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In of the 35 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on March 31, 2026. You may want to consider a long position or call options on PGEN as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PGEN just turned positive on March 26, 2026. Looking at past instances where PGEN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
PGEN moved above its 50-day moving average on April 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PGEN crossed bullishly above the 50-day moving average on April 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PGEN broke above its upper Bollinger Band on March 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PGEN entered a downward trend on March 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (67.568) is normal, around the industry mean (26.452). P/E Ratio (0.000) is within average values for comparable stocks, (46.078). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.789). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (320.063).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company, which engages in the research and development of synthetic biology technologies.
Industry Biotechnology
Advertisement